Welcome to Paid Research Studies




  • Conditions:   Breast Neoplasms;   Musculoskeletal Pain
    Interventions:   Behavioral: Hypnosis;   Behavioral: Attention Control
    Sponsors:   Icahn School of Medicine at Mount Sinai;   National Center for Complementary and Integrative Health (NCCIH)
    Recruiting

  • Conditions:   Aromatase Inhibitor Induced Musculoskeletal Syndrome (AIMSS);   Breast Cancer
    Interventions:   Diagnostic Test: Initial blood draw;   Diagnostic Test: Initial SWE ultrasound;   Diagnostic Test: Blood draw at three months;   Diagnostic Test: Blood draw at six months;   Diagnostic Test: SWE ultrasound at six months
    Sponsor:   University of Arizona
    Recruiting

  • Conditions:   Estrogen Receptor-positive Breast Cancer;   Musculoskeletal Complications;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IA Breast Cancer;   Stage IB Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: anastrozole;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
    Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Neoplasms, Connective and Soft Tissue;   Bone Neoplasms
    Intervention:   Other: Observation
    Sponsor:   Ohio State University Comprehensive Cancer Center
    Recruiting

  • Condition:   Malignant Bone Tumors
    Interventions:   Radiation: Radiation;   Procedure: Malignant Tumor Surgery
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Leukemia;   Adenomatous Polyposis;   Adrenocortical Carcinoma;   AML;   BAP1 Tumor Predisposition Syndrome;   Carney Complex;   Choroid Plexus Carcinoma;   Constitutional Mismatch Repair Deficiency Syndrome;   Diamond-Blackfan Anemia;   DICER1 Syndrome;   Dyskeratosis Congenita;   Emberger Syndrome;   Familial Acute Myeloid Leukemia;   Familial Adenomatous Polyposis;   Fanconi Anemia;   Familial Cancer;   Familial Wilms Tumor;   Familial Neuroblastoma;   GIST;   Hereditary Breast and Ovarian Cancer;   Hereditary Paraganglioma-Pheochromocytoma Syndrome;   Hodgkin Lymphoma;   Juvenile Polyposis;   Li-Fraumeni Syndrome;   Lynch Syndrome;   MDS;   Melanoma Syndrome;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Neuroblastoma;   Neurofibromatosis Type 1;   Neurofibromatosis Type II;   Nevoid Basal Cell Carcinoma Syndrome;   Non Hodgkin Lymphoma;   Noonan Syndrome and Other Rasopathy;   Overgrowth Syndromes;   Pancreatic Cancer;   Peutz-Jeghers Syndrome;   Pheochromocytoma/Paraganglioma;   PTEN Hamartoma Tumor Syndrome;   Retinoblastoma;   Rhabdoid Tumor Predisposition Syndrome;   Rhabdomyosarcoma;   Rothmund-Thomson Syndrome;   Tuberous Sclerosis;   Von Hippel-Lindau Disease
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Conditions:   Prostate Cancer;   Castration-resistant Prostate Cancer;   Castration-resistant Prostate Cancer Metastatic to Bone
    Interventions:   Procedure: Blood Tests;   Procedure: CT scan and bone scan;   Procedure: FACBC PET/MRI in a subset of participants;   Drug: Radium-223 dichloride
    Sponsors:   Massachusetts General Hospital;   Bayer
    Recruiting

  • Conditions:   Skull Base Neoplasm;   Cellular Pathology
    Intervention:   Other: Observation
    Sponsor:   University of Pittsburgh
    Recruiting

  • Condition:   Prostate Cancer Metastatic to Bone
    Interventions:   Drug: Radium Ra 223 Dichloride;   Radiation: Radiation
    Sponsors:   University of Utah;   Bayer
    Recruiting

  • Conditions:   Bone Metastases;   Breast Cancer
    Intervention:   Drug: Merestinib
    Sponsors:   University of Utah;   Eli Lilly and Company
    Recruiting

  • Conditions:   Bone Metastases;   Breast Cancer;   Pain
    Intervention:   Drug: Syndros
    Sponsor:   University of Arizona
    Recruiting

  • Conditions:   Central Nervous System Tumor;   Brain Tumor;   Spinal Tumor
    Intervention:  
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: LN-145;   Drug: IL-2;   Drug: Mesna;   Behavioral: Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Iovance Biotherapeutics, Inc.
    Recruiting

  • Condition:   Giant Cell Tumor of Bone
    Intervention:   Drug: Zoledronic Acid
    Sponsor:   St. Louis University
    Recruiting

  • Conditions:   Tumor-Induced Osteomalacia;   Oncogenic Osteomalacia
    Intervention:   Drug: BGJ398
    Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
    Recruiting

  • Condition:   Bone Cancer
    Interventions:   Drug: Stereotactic Body Radiation Therapy (SBRT);   Device: Stereotactic Linear Accelerator
    Sponsor:   Dana-Farber Cancer Institute
    Recruiting

  • Conditions:   Brain Tumors and/or Solid Tumors Including;   Brain Stem Glioma;   High Grade CNS Tumors;   Ependymoma;   Medulloblastoma;   Craniopharyngioma;   Low Grade CNS Tumors;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Ewing Sarcoma;   Osteosarcoma;   Rhabdomyosarcoma;   Neuroblastoma;   Other
    Intervention:   Drug: Methionine
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Spinal Tumor
    Intervention:   Device: Magnetic Resonance Imaging
    Sponsor:   Case Comprehensive Cancer Center
    Recruiting

  • Conditions:   Secondary Malignant Neoplasm of Vertebral Column;   Spine Metastases
    Interventions:   Procedure: Thermal Ablation Procedure;   Radiation: Stereotactic Spine Radiosurgery (SSRS);   Behavioral: Symptom Questionnaires
    Sponsors:   M.D. Anderson Cancer Center;   Medtronic
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Neoplasms of Uncertain or Unknown Behavior
    Interventions:   Drug: Avelumab;   Drug: Utomilumab;   Drug: PF-04518600;   Radiation: Radiation;   Drug: Cisplatin
    Sponsors:   M.D. Anderson Cancer Center;   Pfizer
    Recruiting

  • Conditions:   Hormone-Resistant Prostate Cancer;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Prostate Carcinoma;   Prostate Adenocarcinoma;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Biological: Pembrolizumab;   Biological: pTVG-HP Plasmid DNA Vaccine
    Sponsors:   University of Wisconsin, Madison;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Recurrent Prostate Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Lymph Nodes;   Oligometastasis;   Prostate Adenocarcinoma;   PSA Failure
    Interventions:   Radiation: Hypofractionated Radiation Therapy;   Radiation: Intensity-Modulated Radiation Therapy;   Procedure: Metastasectomy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Stereotactic Body Radiation Therapy
    Sponsor:   University of Utah
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Intervention:   Drug: IACS-010759
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Brain Tumor;   Head and Neck Tumor;   Skull Base Tumor
    Intervention:   Procedure: PET scan
    Sponsors:   Massachusetts General Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Healthy Control;   Localized Urothelial Carcinoma of the Renal Pelvis and Ureter;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Malignant Neoplasm in the Soft Tissues;   Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter;   Recurrent Bladder Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Urothelial Carcinoma of the Renal Pelvis and Ureter;   Stage IV Bladder Cancer;   Stage IV Bladder Urothelial Carcinoma;   Stage IV Prostate Cancer
    Interventions:   Other: Cytology Specimen Collection Procedure;   Other: Laboratory Biomarker Analysis
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Osteomalacia
    Intervention:   Combination Product: 68Ga-DOTATATE PET/CT
    Sponsor:   Mayo Clinic
    Recruiting

  • Conditions:   Glioma of Brain;   Craniopharyngioma;   Ependymoma;   Germ Cell Tumor
    Interventions:   Drug: Memantine;   Other: Placebo;   Other: Cognitive Assessment
    Sponsors:   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Breast Cancer;   Joint Pain
    Interventions:   Dietary Supplement: Curcumin;   Other: Placebo;   Other: Nanoemulsion;   Other: Quality-of-Life Assessment;   Behavioral: Questionnaire
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cancer Bone;   Bone Tumors
    Intervention:  
    Sponsor:   Beth Israel Deaconess Medical Center
    Recruiting

  • Conditions:   Hematological Malignancies;   Chronic Hypoxemic Respiratory Failure;   Blood And Marrow Transplantation;   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Interventions:   Other: Non-Invasive Positive Pressure Ventilation (NIPPV);   Other: High Flow Nasal Cannula Oxygen Therapy
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Malignant Neoplasm of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasm of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Intervention:   Drug: Gemcitabine
    Sponsors:   M.D. Anderson Cancer Center;   James B. and Lois R. Archer Charitable Foundation;   Gateway for Cancer Research
    Recruiting

  • Conditions:   Malignant Neoplasm of Breast;   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Digestive Organs;   Malignant Neoplasms of Eye Brain and Other Parts of Central Nervous System;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Ill-defined Secondary and Unspecified Sites;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Respiratory and Intrathoracic Organs;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic
    Interventions:   Drug: TAK-228;   Drug: Paclitaxel;   Drug: Carboplatin
    Sponsors:   M.D. Anderson Cancer Center;   Takeda
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Pelvic Tumor
    Intervention:   Drug: Tranexamic Acid
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Female Genital Organs;   Malignant Neoplasms of Independent (Primary) Multiple Sites;   Malignant Neoplasms of Lip Oral Cavity and Pharynx;   Malignant Neoplasms of Male Genital Organs;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Malignant Neoplasms of Thyroid and Other Endocrine Glands;   Malignant Neoplasms of Urinary Tract;   Melanoma and Other Malignant Neoplasms of Skin
    Interventions:   Drug: Cyclophosphamide;   Drug: Etoposide;   Procedure: NK Cell Infusion;   Drug: Mesna
    Sponsor:   M.D. Anderson Cancer Center
    Recruiting

  • Conditions:   Prostate Cancer;   Bone Metastases
    Intervention:   Drug: [68Ga]P15-041
    Sponsor:   Five Eleven Pharma, Inc.
    Recruiting

  • Conditions:   Malignant Neoplasm;   Metastatic Malignant Neoplasm in the Bone;   Pain
    Interventions:   Radiation: External Beam Radiation Therapy;   Radiation: Palliative Radiation Therapy;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Panhypopituitarism;   Gigantism/Acromegaly;   Prolactinoma;   Cushing Disease
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Cancer;   Skin Fibroblasts;   Muscle Weakness
    Intervention:   Dietary Supplement: Niagen
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Conditions:   Cancer;   Hematologic Disorder;   Rheumatologic Disorder;   Infertility
    Intervention:   Procedure: Ovarian Cryopreservation
    Sponsor:   Vlad Radulescu
    Recruiting

  • Conditions:   Cancer;   Lymphoma;   Pancreatic Cancer;   Glioblastoma Multiforme;   Sarcoma;   Breast Cancer;   Bladder Cancer;   Renal Cancer;   Ovarian Cancer;   Refractory Cancer;   Refractory Neoplasm;   Refractory Non-Hodgkin Lymphoma;   Refractory Brain Tumor;   Pancreatic Adenocarcinoma;   Resistant Cancer;   Neoplasm Metastasis;   Neoplasm of Bone;   Neoplasm, Breast;   Neoplasm of Lung;   Neoplasms,Colorectal;   Neoplasms Pancreatic;   Malignant Glioma;   Malignancies;   Malignancies Multiple;   Bone Metastases;   Bone Neoplasm;   Bone Cancer;   Pancreas Cancer;   Pancreatic Neoplasms;   Breast Neoplasms
    Interventions:   Drug: 9-ING-41;   Drug: Gemcitabine - 21 day cycle;   Drug: Doxorubicin.;   Drug: Lomustine;   Drug: Carboplatin.;   Drug: Nab paclitaxel.;   Drug: Paclitaxel.;   Drug: Gemcitabine - 28 day cycle
    Sponsors:   Actuate Therapeutics Inc.;   Developmental Therapeutics Consortium
    Recruiting

  • Conditions:   Malignant Neoplasms of Bone and Articular Cartilage;   Malignant Neoplasms of Mesothelial and Soft Tissue;   Synovial Sarcoma;   Myxoid Liposarcoma
    Interventions:   Biological: Modified T Cells;   Drug: Cyclophosphamide;   Biological: IL-2;   Biological: LV305;   Biological: CMB305
    Sponsors:   M.D. Anderson Cancer Center;   Immune Design
    Recruiting

  • Conditions:   Pheochromocytoma;   Paraganglioma;   Inherited Cancer Syndrome;   Associated Conditions;   Kidney Neoplasms;   Bone Cancer;   Thyroid Neoplasms;   Other Cancer
    Intervention:   Genetic: Genetic screening
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting

  • Condition:   Giant Cell Tumors
    Intervention:  
    Sponsors:   Daiichi Sankyo, Inc.;   SSS International Clinical Research GmBH
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Bone Sarcoma;   Osteosarcoma;   Chondrosarcoma;   Ewing's Sarcoma;   Osseous Sarcoma;   Bone Neoplasm
    Interventions:   Behavioral: Toronto Extremity Salvage Score;   Behavioral: Musculoskeletal Tumor Society Score;   Behavioral: Timed Get Up and Go Test;   Diagnostic Test: Orthogonal Radiographs;   Diagnostic Test: Weight Bearing for lower extremities only;   Diagnostic Test: Range of Motion;   Diagnostic Test: Osteocalcin;   Diagnostic Test: Amino terminal propepetide of type 1 collagen;   Diagnostic Test: N-telopeptide of type 1 collagen
    Sponsor:   Memorial Sloan Kettering Cancer Center
    Recruiting

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Etanercept;   Drug: Infliximab;   Drug: Adalimumab;   Drug: Placebo
    Sponsors:   Georgetown University;   National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS);   University of Maryland;   Washington D.C. Veterans Affairs Medical Center;   Washington Hospital Center;   Patient-Centered Outcomes Research Institute;   Arthritis and Pain Associates of PG County;   Arthritis & Rheumatism Associates, P.C.;   Rheumatology Associates of Baltimore, L.L.C.;   The Arthritis Clinic of Northern Virginia, P.C.;   Arthritis and Rheumatic Disease Associates, P.C.
    Recruiting

  • Conditions:   Cockayne Syndrome;   Skin Neoplasms;   Xeroderma Pigmentosum;   Trichothiodystrophy;   Genodermatosis
    Intervention:  
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Craniopharyngioma;   Hypothalamic Obesity
    Interventions:   Drug: Syntocinon;   Drug: Placebo (for Syntocinon)
    Sponsor:   Shana McCormack, MD
    Recruiting

  • Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   Estrogen Receptor Positive;   HER2/Neu Negative;   Metastatic Breast Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Progesterone Receptor Positive;   Prognostic Stage IV Breast Cancer AJCC v8
    Interventions:   Drug: Anastrozole;   Drug: Exemestane;   Drug: Fulvestrant;   Drug: Letrozole;   Drug: Palbociclib;   Radiation: Radiation Therapy;   Drug: Tamoxifen
    Sponsors:   Emory University;   Pfizer
    Recruiting

  • Conditions:   Tumor Induced Osteomalcia;   Osteomalacia;   Familial Tumoral Calcinosis
    Intervention:  
    Sponsor:   National Institute of Dental and Craniofacial Research (NIDCR)
    Recruiting

  • Condition:   Bone Metastases
    Intervention:   Radiation: radiosurgical hypophysectomy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins;   Accuray Incorporated
    Recruiting

  • Conditions:   Adrenal Gland Neoplasm;   Hypertension;   Bone Diseases, Metabolic;   Cardiovascular Disease;   Hyperinsulinemia
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Bladder Small Cell Carcinoma;   Clear Cell Renal Cell Carcinoma;   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Kidney Medullary Carcinoma;   Metastatic Malignant Neoplasm in the Bone;   Metastatic Penile Carcinoma;   Metastatic Renal Cell Carcinoma;   Renal Pelvis Urothelial Carcinoma;   Sarcomatoid Renal Cell Carcinoma;   Squamous Cell Carcinoma of the Penis;   Stage III Bladder Adenocarcinoma AJCC v6 and v7;   Stage III Bladder Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Bladder Urothelial Carcinoma AJCC v6 and v7;   Stage III Penile Cancer AJCC v7;   Stage III Renal Cell Cancer AJCC v7;   Stage III Renal Pelvis Cancer AJCC v7;   Stage III Ureter Cancer AJCC v7;   Stage III Urethral Cancer AJCC v7;   Stage IIIa Penile Cancer AJCC v7;   Stage IIIb Penile Cancer AJCC v7;   Stage IV Bladder Adenocarcinoma AJCC v7;   Stage IV Bladder Squamous Cell Carcinoma AJCC v7;   Stage IV Bladder Urothelial Carcinoma AJCC v7;   Stage IV Penile Cancer AJCC v7;   Stage IV Renal Cell Cancer AJCC v7;   Stage IV Renal Pelvis Cancer AJCC v7;   Stage IV Ureter Cancer AJCC v7;   Stage IV Urethral Cancer AJCC v7;   Ureter Urothelial Carcinoma;   Urethral Urothelial Carcinoma
    Interventions:   Drug: Cabozantinib S-malate;   Biological: Ipilimumab;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Osteoarthritis;   Cancer Pain;   Recurrent Low Back Pain
    Intervention:   Drug: Investigational medical product (IMP) administered in parent study
    Sponsors:   Pfizer;   Eli Lilly and Company
    Recruiting

  • Condition:   Arthritis, Rheumatoid
    Interventions:   Drug: tofacitinib;   Biological: adalimumab;   Biological: etanercept
    Sponsor:   Pfizer
    Recruiting

  • Condition:   Rheumatoid Arthritis
    Interventions:   Drug: Olokizumab q4w;   Drug: Olokizumab q2w;   Drug: Placebo q2w
    Sponsors:   R-Pharm;   Quintiles, Inc.;   OCT Clinical Trials;   Mene Research
    Recruiting

  • Conditions:   Bone Pain;   Metastatic Malignant Neoplasm in the Bone;   Plasma Cell Myeloma
    Interventions:   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Radiation: Radiation Therapy
    Sponsors:   University of Southern California;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Cushing's Disease;   Acromegaly;   Neuroendocrine Tumors;   Pituitary Tumors;   Ectopic ACTH Secreting (EAS) Tumors;   Dumping Syndrome;   Prostate Cancer;   Melanoma Negative for bRAF;   Melanoma Negative for nRAS
    Intervention:   Drug: Pasireotide
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Palatal Neoplasms;   Lip Neoplasm;   Gingival Neoplasms;   Leukoplakia, Oral;   Tongue Neoplasms;   Oropharyngeal Neoplasms;   Oral Ulcer
    Intervention:   Device: OncAlert
    Sponsors:   Vigilant Biosciences, Inc.;   Pearl Pathways
    Recruiting